Document is current
Any future updates will be listed below
-
Authors
Shien, Tadahiko https://orcid.org/0000-0003-3202-5512
Hara, Fumikata
Aogi, Kenjiro
Yanagida, Yasuhiro
Tsuneizumi, Michiko
Yamamoto, Naohito
Matsumoto, Hiroshi
Suto, Akihiko
Watanabe, Kenichi
Harao, Michiko
Kanbayashi, Chizuko
Itoh, Mitsuya
Kadoya, Takayuki
Anan, Keisei
Maeda, Shigeto
Sasaki, Keita
Ogawa, Gakuto
Saji, Shigehira
Fukuda, Haruhiko
Iwata, Hiroji
,
- License Information
-
More Information
Article History
Received: 6 March 2025
Revised: 13 May 2025
Accepted: 17 June 2025
First Online: 4 July 2025
Competing interests
: TS reported grants from the Ministry of Health, Labour and Welfare of Japan and from the Japan Agency for Medical Research and Development (AMED) during the conduct of the study, as well as personal fees from Pfizer, Chugai, Lilly, Daiichi Sankyo, MSD, Eisai, AstraZeneca, Taiho, Nihon Kayaku, Gilead. K Anan reported personal fees from EISAI, Daiichi Sankyo, Eli Lilly, Chugai Pharmaceutical, Pfizer, AstraZeneca, MSD, Kyowa Kirin. K Aogi reported the grant from Chugai Pharmaceutical and the personal fee from Eisai, Chugai Pharmaceutical, AstraZeneca, Eli Lilly Japan, Taiho Pharmaceutical, Daiichi Sankyo, Pfizer. FH reported the personal fees from Pfizer, Ili Lilly, Daiichi Sankyo, Kyowa Kirin, Chugai, MSD. TK reported the personal fees from Ili Lilly. GO reported the grants from Japan Agency for Medical Research and Development and Ministry of Health, Labour and Welfare, Japan. HF reported the grants from National Cancer Center and AstraZeneca, Ono Pharmaceutical Co., Ltd, Chugai Pharmaceutical Co., Ltd, Takeda Pharmaceutical Company Limited and the personal fees from Chugai Pharmaceutical Co., Ltd., Kyowa Kirin Co., Ltd., CMIC Co., Ltd. SS reported the grants from Taiho, Eisai, Chugai, Takeda, MSD, AstraZeneca, Daiichi Sankyo, Gilead, Eli Lilly, Sanofi and the personal fees from Chugai, Kyowa Kirin, MSD, Novartis, Eisai, Takeda, Daiichi Sankyo, Eli Lilly, AstraZeneca, Pfizer, Taiho, Ono, Nippon Kayaku, Gilead, Exact Sciences. HI reported the grants from Pfizer and Chugai, Daiichi Sankyo, AstraZeneca and personal fees from Daiichi Sankyo, Chugai, AstraZeneca, Lilly, MSD, Pfizer, Taiho, Kyowa Kirin. No other disclosures were reported.
: All methods were performed by the relevant guidelines and regulations. This study was approved by the Ethics Committee of National Cancer Center Hospital East Certified Review Board, and the approval reference number is CRB3180009. Informed consent was obtained from all participants involved in the study.
